Helicobacter-pylori Infektion - ein Update 2004

P. Malfertheiner; U. Peitz; K. Wolle; G. Treiber

doi:10.1055/s-2004-831344

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2004; 129(34/35): 1821-1826
DOI: 10.1055/s-2004-831344

Übersichten

Gastroenterologie/Infektiologie
© Georg Thieme Verlag Stuttgart · New York

Helicobacter-pylori Infektion - ein Update 2004

Helicobacter pylori infection - update for the clinician 2004P. Malfertheiner¹ , U. Peitz¹ , K. Wolle¹ , G. Treiber¹

¹Klinik für Gastroenterologie, Hepatologie und Infektiologie der Otto-von-Guericke-Universität Magdeburg

Abstract

Full Text

References

Literatur

1 Birkner B, Hotz J, Labenz J. et al . Kurzgefasste Leitlinie zum Dyspepsie-Management. Dtsch Med Wochenschr. 2004; 129 (18) 1032-1034
2 Blaser M J. Hypothesis: the changing relationship of H.p. and humans: implications for health and disease. J Infect Dis. 1999; 179 1523-1530
3 Brenner H, Arndt V, Stegmaier C. et al . Is H.p. infection a necessary condition for noncardia gastric cancer?. Am J Epidemiol. 2004; 159 252-258
4 Chan F K, Chung S C, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001; 344 967-973
5 Chan F K, To K F, Wu J C. et al . Eradication of H.p. and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002; 359 9-13
6 Chiba N, Veldhuyzen Van Zanten S JO, Escobedo S. et al . Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled trial of H.p. positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther. 2004; 19 349-358
7 Chiba N, Veldhuyzen Van Zanten S JO, Sinclair P. et al . Treating H.p. infection in primary care patients with uninvestigated dyspepsis: the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised controlled trial. Brit Med J. 2002; 324 1-7
8 Churin Y, Al-Ghoul L, Kepp O. et al . Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol. 2003; 28 (161) 249-255
9 Dore M P, Osato M S, Malaty H M. et al . Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients. Helicobacter. 2000; 5 165-168
10 El Omar E M, Rabkin C S, Gammon M D. et al . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003; 124 1193-201
11 Fischbach W, Goebeler-Kolve M E, Dragosics B. et al . Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004; 53 34-37
12 Gisbert J, Calvet X, Bujanda L. et al . ’Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter. 2003; 8 90-94
13 Glupczynski Y, Megraud F, Lopez-Brea M. et al . European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001; 20 820-823
14 Glynn M K, Friedman C R, Gold B D. et al . Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis. 2002; 35 1059-1065
15 Granquist A, Bredberg A, Sveger T. et al . A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents. Acta Paediatr. 2002; 91 636-640
16 Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms. Dtsch Med Wochenschr. 2003; 128 1878-1883
17 Heuberger F, Pantoflickowa D, Gassner M. et al . H.p. infection in Swiss adolescents. Prevalence and risk factors. Eur J Gastroenterol Hepatol. 2003; 15 179-183
18 Huang J, Hunt R. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther. 1999; 13 857-64
19 Kist M, Glocker E. Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung. Epidemiol Bull. 2003; 47 389-391
20 Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95 2-8
21 Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al . Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004; 53 12-20
22 Labenz J, Blum A L, Bolten W W. et al . Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in H.p. positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002; 51 329-335
23 Lai K C, Lam S K, Chu K M. et al . Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002; 346 2033-2038
24 Leodolter A, Dominguez-Munoz J E, Von Arnim U. et al . Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol. 1999; 94 2100-2104
25 Leodolter A, Malfertheiner P. Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion. Dtsch Med Wochenschr. 2001; 126 207-209
26 Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of H. pylori infection. Dig Dis. 2001; 19 116-122
27 Leodolter A, Peitz U, Ebert M P. et al . Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy. Am J Gastroenterol. 2002; 97 1682-1686
28 Leodolter A, Vaira D, Bazzoli F. et al . European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther. 2003; 18 927-931
29 Leodolter A, Wolle K, Peitz U. et al . Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status. Diagn Microbiol Infect Dis. 2004; 48 145-147
30 Malfertheiner P. H.p. eradication does not exacerbate gastro-oesophageal reflux disease. Gut. 2004; 53 312-313
31 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16 167-180
32 Malfertheiner P, Mössner J, Fischbach W. et al . H.p. eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2003; 15 615-625
33 Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy?. Can J Gastroenterol. 2003; 17 (Suppl B) 53B-57B
34 Manes G, Menchise A, De Nucci C. et al . Empirical prescribing for dyspepsia. randomised controlled trial of test and treat versus omeprazole treatment. Brit Med J. 2003; 326 1118
35 Mc Coll K EL, Murray L S, Gillen D. et al . Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H.p. testing alone in the management for dyspepsia. Brit Med J. 2002; 324 999-1002
36 Meining A G, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol. 1999; 11 717-720
37 Melo E T, Lopes E P, Almeida J R, Albuquerque H F, Moura I M. Seroprevalence of H. pylori antibodies in medical students and residents in Recife, Brazil. Clin Gastroenterol. 2003; 36 134-8
38 Mitchell H M, Hu P, Chi Y. et al . A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation. Gastroenterology. 1998; 114 256-261
39 Nardone G, Morgner A. Helicobacter pylori and gastric malignancies. Helicobacter. 2003; 8,1 44-52
40 Osato M S, Reddy R, Graham D Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 1999; 12 341-347
41 Peitz U, Leodolter A, Wex T. et al . Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol. 2004; 42 141-146
42 Raymond J, Kalach N, Bergeret M. et al . Prevalence of Helicobacter pylori infection in children according to their age. A retrospective study. Arch Pediatr. 1998; 5 617-620
43 Roma-Giannikou E, Karameris A, Balatsos B. et al . Intrafamilial spread of Helicobacter pylori: a genetic analysis. Helicobacter. 2003; 8 15-20
44 Rothenbacher D, Brenner H. Burden of H.p. and H.p.-related diseases in developed countries: recent developments and future implications. Microbes Infect. 2003; 5 (8) 693-703
45 Schilling D, Demel A, Adamek H E. et al . A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis. 2003; 35 217-221
46 Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347 1175-86
47 Triantafillidis J K, Gikas A, Hyphantis T. et al . Helicobacter pylori infection in hospital workers over a 5-year period. Correlation with demographic and clinical parameters. J Gastroenterol. 2002; 37 1005-1013
48 Uemura N, Okamoto S, Yamamoto S. et al . H.p. infection and the development of gastric cancer. N Engl J Med. 2001; 345 784-789
49 Wolle K, Leodolter A, Malfertheiner P. et al . Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol. 2002; 51 705-9
50 Wong B CY, Lam S K, Wong W M. et al . H.p. eradication to prevent gastric cancer in a high-risk region of China. J Amer Med Assoc. 2004; 291 (2) 187-194

Prof. Dr. P. Malfertheiner

Klinik für Gastroenterologie, Hepatologie und Infektiologie der Otto-von-Guericke-Universität Magdeburg

Leipziger Str. 44

39120 Magdeburg

Phone: 03 91-6 71 31 00

Fax: 03 91-6 71 31 05

Email: peter.malfertheiner@medizin.uni-magdeburg.de